Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

Your Social Media Guide to #BIO2012

Twitter

The BIO International Convention is the largest global event for the biotechnology industry; it attracts the biggest names in biotech and offers key networking and partnering opportunities. The event is also a great opportunity to connect with the online biotech community and we’re ramping up our social media efforts for the 2012 BIO International Convention, beginning on Monday, June 18 in Boston. If you’d like to join the online conversation, here are some tips, tricks, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Picks and Pans – The Buy-Side View for 2012

Survey

What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies? At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , ,

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

alzheimers

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

NIH: Streamlining the Technology Transfer Process

cyclotron

The National Institutes of Health (NIH) is launching the electronic Research Materials catalogue (eRMa) to streamline the federal government’s technology transfer process. “To stay competitive in today’s world, on-line ordering is a requirement. With the launch of this first-of-its kind system, OTT is demonstrating its intention to meet that challenge,” said Mark Rohrbaugh, director of OTT. According to the press release: “The new system will streamline the licensing process by: Providing a website for companies Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,